دورية أكاديمية
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.
| العنوان: | Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. |
|---|---|
| المؤلفون: | Goddard ET; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Linde MH; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Srivastava S; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Klug G; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Shabaneh TB; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Iannone S; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Grzelak CA; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Marsh S; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Riggio AI; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA., Shor RE; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Linde IL; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Guerrero M; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Veatch JR; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Snyder AG; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Welm AL; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA., Riddell SR; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: sriddell@fredhutch.org., Ghajar CM; Public Health Sciences Division/Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Center for Metastasis Research eXcellence (MET-X), Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: cghajar@fredhutch.org. |
| المصدر: | Cancer cell [Cancer Cell] 2024 Jan 08; Vol. 42 (1), pp. 119-134.e12. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Cambridge, Mass. : Cell Press, c2002- |
| مواضيع طبية MeSH: | T-Lymphocytes* , Breast Neoplasms*/therapy, Humans ; Female ; Immune Evasion ; Adoptive Transfer ; Immunotherapy |
| مستخلص: | The period between "successful" treatment of localized breast cancer and the onset of distant metastasis can last many years, representing an unexploited window to eradicate disseminated disease and prevent metastases. We find that the source of recurrence-disseminated tumor cells (DTCs) -evade endogenous immunity directed against tumor neoantigens. Although DTCs downregulate major histocompatibility complex I, this does not preclude recognition by conventional T cells. Instead, the scarcity of interactions between two relatively rare populations-DTCs and endogenous antigen-specific T cells-underlies DTC persistence. This scarcity is overcome by any one of three immunotherapies that increase the number of tumor-specific T cells: T cell-based vaccination, or adoptive transfer of T cell receptor or chimeric antigen receptor T cells. Each approach achieves robust DTC elimination, motivating discovery of MHC-restricted and -unrestricted DTC antigens that can be targeted with T cell-based immunotherapies to eliminate the reservoir of metastasis-initiating cells in patients. Competing Interests: Declaration of interests S.R.R. is a co-founder of Lyell Immunopharma, has research funding from Lyell Immunopharma, and holds equity in Lyell Immunopharma. S.R.R. has patents in the field of cellular therapy unrelated to this work licensed to Juno Therapeutics/Bristol Myers Squibb and Lyell Immunopharma. M.H.L. has served as a consultant for Scribe Biosciences, Inc. S.S. has received research funding from Lyell Immunopharma, has a patent licensed by Lyell Immunopharma, holds equity and has served as a consultant for Lyell Immunopharma outside the submitted work. J.R.V. has intellectual property unrelated to this work licensed to Lyell Immunopharma and has received research grant support form Lyell Immunopharma and Bristol Myers Squibb. (Copyright © 2023 Elsevier Inc. All rights reserved.) |
| التعليقات: | Comment in: Cancer Cell. 2024 Jan 8;42(1):13-15. (PMID: 38194913) |
| References: | Leukemia. 2016 Feb;30(2):492-500. (PMID: 26369987) Sci Rep. 2016 Nov 07;6:36520. (PMID: 27819283) J Leukoc Biol. 2004 Feb;75(2):163-89. (PMID: 14525967) Cancer Cell. 2006 Dec;10(6):515-27. (PMID: 17157791) Nature. 2022 Nov;611(7935):358-364. (PMID: 36323784) Science. 2018 Sep 28;361(6409):. (PMID: 30262472) Int J Cancer. 2007 Jun 1;120(11):2411-7. (PMID: 17294444) Front Oncol. 2022 Mar 21;12:786438. (PMID: 35387130) Hum Gene Ther. 2009 Jun;20(6):630-40. (PMID: 19265475) Cancer Immunol Res. 2019 Jun;7(6):910-922. (PMID: 31043415) Clin Cancer Res. 2011 May 1;17(9):2967-76. (PMID: 21415211) J Immunol Methods. 1990 Apr 17;128(2):189-201. (PMID: 1691237) Br J Cancer. 1992 May;65(5):641-8. (PMID: 1586590) Cell. 2022 May 12;185(10):1694-1708.e19. (PMID: 35447074) JAMA Oncol. 2017 Aug 01;3(8):1094-1101. (PMID: 28426845) Clin Exp Metastasis. 1993 Jan;11(1):103-12. (PMID: 8422701) Cancer Res. 1996 May 1;56(9):2039-44. (PMID: 8616848) Cancer Res. 1989 Nov 1;49(21):6091-7. (PMID: 2790822) Cancer Cell. 2022 Jan 10;40(1):1-2. (PMID: 34861158) Nat Rev Cancer. 2015 Apr;15(4):238-47. (PMID: 25801619) Nat Biotechnol. 2015 Dec;33(12):1287-1292. (PMID: 26524661) N Engl J Med. 2018 Jul 5;379(1):64-73. (PMID: 29972754) Blood Adv. 2019 Jul 9;3(13):2022-2034. (PMID: 31289029) N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870) Nucleic Acids Res. 2020 Jan 8;48(D1):D948-D955. (PMID: 31667505) J Natl Cancer Inst. 1993 Sep 1;85(17):1419-24. (PMID: 7688814) J Immunol. 2018 Jan 15;200(2):459-468. (PMID: 29311388) Semin Cancer Biol. 2021 Jul;72:65-75. (PMID: 31698088) Lancet Oncol. 2020 Jan;21(1):44-59. (PMID: 31786121) Nature. 2017 Jul 13;547(7662):222-226. (PMID: 28678784) N Engl J Med. 2005 Aug 25;353(8):793-802. (PMID: 16120859) J Immunother Cancer. 2020 Apr;8(1):. (PMID: 32269142) Cancer Res. 1991 Sep 1;51(17):4712-5. (PMID: 1873815) Pigment Cell Melanoma Res. 2009 Jun;22(3):283-95. (PMID: 19175523) Cancer Cell. 2008 Jan;13(1):58-68. (PMID: 18167340) Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772) J Immunol. 1999 May 15;162(10):5838-45. (PMID: 10229818) Histopathology. 2018 Jul;73(1):68-80. (PMID: 29465777) J Clin Invest. 2021 Aug 16;131(16):. (PMID: 34396986) Curr Opin Immunol. 1992 Oct;4(5):647-55. (PMID: 1418733) J Natl Cancer Inst. 2022 Mar 8;114(3):391-399. (PMID: 34747484) N Engl J Med. 2017 Nov 9;377(19):1836-1846. (PMID: 29117498) J Transl Med. 2018 May 30;16(1):147. (PMID: 29848327) Cancer Cell. 2021 Feb 8;39(2):193-208.e10. (PMID: 33357452) Sci Transl Med. 2021 Apr 28;13(591):. (PMID: 33910979) BMC Cancer. 2019 Mar 4;19(1):200. (PMID: 30832597) Nat Commun. 2020 Oct 5;11(1):4977. (PMID: 33020483) J Virol. 2000 May;74(10):4465-73. (PMID: 10775582) Sci Signal. 2018 Aug 21;11(544):. (PMID: 30131370) J Cell Biol. 1997 Apr 7;137(1):231-45. (PMID: 9105051) Eur J Cancer. 2021 Sep;154:128-137. (PMID: 34265505) Gene Ther. 2000 Dec;7(23):2036-40. (PMID: 11175316) Nat Rev Clin Oncol. 2023 Jan;20(1):49-62. (PMID: 36418477) Nat Med. 2018 Jun;24(6):724-730. (PMID: 29867227) J Immunother Cancer. 2014 Oct 14;2(1):36. (PMID: 25317334) J Clin Oncol. 2015 Feb 20;33(6):540-9. (PMID: 25154820) Cancer Immunol Res. 2015 Feb;3(2):125-35. (PMID: 25212991) Nat Genet. 2019 Jul;51(7):1113-1122. (PMID: 31209394) Int J Cancer. 2001 Aug 15;93(4):566-70. (PMID: 11477561) Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9. (PMID: 1350088) Nat Med. 2021 Sep;27(9):1544-1552. (PMID: 34253928) Cancer Res. 2002 Apr 1;62(7):2162-8. (PMID: 11929839) Nat Cell Biol. 2019 Feb;21(2):238-250. (PMID: 30664790) Invasion Metastasis. 1983;3(1):22-31. (PMID: 6677618) Cancer Immunol Res. 2017 Jul;5(7):516-523. (PMID: 28619968) Cancer Immunol Immunother. 2008 Feb;57(2):271-80. (PMID: 17646988) Blood Adv. 2017 Feb 14;1(6):407-416. (PMID: 29296956) Nature. 2016 Dec 22;540(7634):552-558. (PMID: 27974799) N Engl J Med. 2019 May 2;380(18):1726-1737. (PMID: 31042825) Science. 2018 Jun 15;360(6394):. (PMID: 29773669) Nucleic Acids Res. 2011 Nov;39(21):e143. (PMID: 21911364) Nat Cell Biol. 2013 Jul;15(7):807-17. (PMID: 23728425) Lancet. 1994 May 14;343(8907):1177-83. (PMID: 7909866) Cancer Immunol Immunother. 2021 Dec;70(12):3501-3511. (PMID: 33899130) Immunity. 2018 Feb 20;48(2):271-285.e5. (PMID: 29466757) N Engl J Med. 2020 Feb 27;382(9):810-821. (PMID: 32101663) N Engl J Med. 2018 Feb 1;378(5):449-459. (PMID: 29385376) Nature. 1990 Nov 15;348(6298):252-4. (PMID: 1700304) J Immunol. 2005 Mar 1;174(5):2563-72. (PMID: 15728462) J Clin Oncol. 2014 Dec 1;32(34):3848-57. (PMID: 25366688) NPJ Breast Cancer. 2020 Oct 30;6:59. (PMID: 33145402) PLoS One. 2012;7(3):e33093. (PMID: 22427958) Clin Cancer Res. 2013 Jun 15;19(12):3153-64. (PMID: 23620405) J Natl Cancer Inst. 1999 Jan 6;91(1):80-5. (PMID: 9890174) Cancer. 2005 Mar 1;103(5):884-91. (PMID: 15666325) |
| معلومات مُعتمدة: | P30 CA015704 United States CA NCI NIH HHS; R01 CA114536 United States CA NCI NIH HHS; R01 CA249528 United States CA NCI NIH HHS; R01 CA252874 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: CAR T cell; T cell; TCR T cell; breast cancer metastasis; disseminated tumor cells; immune evasion; immunotherapy; tumor dormancy; tumor microenvironment; vaccine |
| تواريخ الأحداث: | Date Created: 20240109 Date Completed: 20240111 Latest Revision: 20240312 |
| رمز التحديث: | 20240312 |
| مُعرف محوري في PubMed: | PMC10864018 |
| DOI: | 10.1016/j.ccell.2023.12.011 |
| PMID: | 38194912 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1878-3686 |
|---|---|
| DOI: | 10.1016/j.ccell.2023.12.011 |